STOCK TITAN
  1. Home
  2. News
  3. IVBIY
  4. 2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Date of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) from Phase 1 Clinical Studies in Advanced Colorectal Cancer

2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Date of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) from Phase 1 Clinical Studies in Advanced Colorectal Cancer

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Positive)
Tags
clinical trial
Rhea-AI Summary
Innovent Biologics presented Phase 1 clinical data for IBI363, a first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein, at ASCO 2025. The study evaluated IBI363 both as monotherapy and in combination with bevacizumab for advanced colorectal cancer. As monotherapy (n=68), IBI363 achieved a median overall survival of 16.1 months, significantly higher than historical standard treatments (6.4-9.3 months), with a confirmed ORR of 13.6% at 1 mg/kg Q2W. In combination with bevacizumab (n=73), the treatment showed a 15.1% confirmed ORR and 61.6% disease control rate, with median PFS of 4.7 months. Notably, patients without liver metastases showed better outcomes with 31.3% ORR and 7.4 months PFS. The safety profile was manageable, with 27.9% and 35.6% of patients experiencing Grade 3+ TRAEs in monotherapy and combination therapy, respectively.
Innovent Biologics ha presentato i dati clinici di Fase 1 per IBI363, una proteina di fusione bispecifica di nuova generazione PD-1/IL-2α-bias, all'ASCO 2025. Lo studio ha valutato IBI363 sia come monoterapia che in combinazione con bevacizumab per il trattamento del carcinoma colorettale avanzato. In monoterapia (n=68), IBI363 ha raggiunto una sopravvivenza globale mediana di 16,1 mesi, significativamente superiore rispetto ai trattamenti standard storici (6,4-9,3 mesi), con un tasso di risposta obiettiva confermata (ORR) del 13,6% alla dose di 1 mg/kg ogni due settimane. In combinazione con bevacizumab (n=73), il trattamento ha mostrato un ORR confermato del 15,1% e un tasso di controllo della malattia del 61,6%, con una sopravvivenza libera da progressione mediana (PFS) di 4,7 mesi. In particolare, i pazienti senza metastasi epatiche hanno ottenuto risultati migliori, con un ORR del 31,3% e una PFS di 7,4 mesi. Il profilo di sicurezza è risultato gestibile, con il 27,9% e il 35,6% dei pazienti che hanno riportato eventi avversi correlati al trattamento di grado 3 o superiore rispettivamente in monoterapia e in terapia combinata.
Innovent Biologics presentó datos clínicos de Fase 1 para IBI363, una proteína de fusión bispecífica innovadora que actúa como PD-1/IL-2α-bias, en ASCO 2025. El estudio evaluó IBI363 tanto en monoterapia como en combinación con bevacizumab para el cáncer colorrectal avanzado. En monoterapia (n=68), IBI363 logró una supervivencia global media de 16,1 meses, significativamente superior a los tratamientos estándar históricos (6,4-9,3 meses), con una tasa de respuesta objetiva confirmada (ORR) del 13,6% a 1 mg/kg cada dos semanas. En combinación con bevacizumab (n=73), el tratamiento mostró una ORR confirmada del 15,1% y una tasa de control de la enfermedad del 61,6%, con una mediana de supervivencia libre de progresión (PFS) de 4,7 meses. Notablemente, los pacientes sin metástasis hepáticas obtuvieron mejores resultados con un ORR del 31,3% y una PFS de 7,4 meses. El perfil de seguridad fue manejable, con un 27,9% y un 35,6% de pacientes experimentando eventos adversos relacionados con el tratamiento (TRAEs) de grado 3 o superior en monoterapia y terapia combinada, respectivamente.
Innovent Biologics는 ASCO 2025에서 IBI363의 1상 임상 데이터를 발표했습니다. IBI363은 최초의 PD-1/IL-2α-바이어스 이중특이성 항체 융합 단백질입니다. 본 연구는 진행성 대장암 환자에서 IBI363을 단독 요법과 베바시주맙 병용 요법으로 평가했습니다. 단독 요법군(n=68)에서 IBI363은 중간 전체 생존 기간이 16.1개월로, 기존 표준 치료(6.4-9.3개월)보다 유의하게 길었으며, 1 mg/kg 2주 간격 투여 시 확인된 객관적 반응률(ORR)은 13.6%였습니다. 베바시주맙과 병용 시(n=73) 확인된 ORR은 15.1%, 질병 조절률은 61.6%였으며, 중간 무진행 생존 기간(PFS)은 4.7개월이었습니다. 특히 간 전이가 없는 환자들은 31.3%의 ORR과 7.4개월의 PFS로 더 좋은 결과를 보였습니다. 안전성 프로파일은 관리 가능했으며, 단독 요법과 병용 요법에서 각각 27.9%와 35.6%의 환자가 3등급 이상의 치료 관련 이상반응(TRAE)을 경험했습니다.
Innovent Biologics a présenté les données cliniques de phase 1 pour IBI363, une protéine de fusion bispécifique de première classe ciblant PD-1/IL-2α-bias, lors de l'ASCO 2025. L'étude a évalué IBI363 en monothérapie ainsi qu'en combinaison avec le bevacizumab pour le cancer colorectal avancé. En monothérapie (n=68), IBI363 a atteint une survie globale médiane de 16,1 mois, nettement supérieure aux traitements standards historiques (6,4-9,3 mois), avec un taux de réponse objective confirmée (ORR) de 13,6 % à 1 mg/kg toutes les deux semaines. En combinaison avec le bevacizumab (n=73), le traitement a montré un ORR confirmé de 15,1 % et un taux de contrôle de la maladie de 61,6 %, avec une survie sans progression médiane (PFS) de 4,7 mois. Notamment, les patients sans métastases hépatiques ont présenté de meilleurs résultats avec un ORR de 31,3 % et une PFS de 7,4 mois. Le profil de sécurité était gérable, avec 27,9 % et 35,6 % des patients présentant des événements indésirables liés au traitement de grade 3 ou plus en monothérapie et en thérapie combinée, respectivement.
Innovent Biologics präsentierte auf der ASCO 2025 Phase-1-Klinikdaten zu IBI363, einem neuartigen PD-1/IL-2α-bias bispezifischen Antikörper-Fusionsprotein. Die Studie bewertete IBI363 sowohl als Monotherapie als auch in Kombination mit Bevacizumab bei fortgeschrittenem kolorektalem Krebs. In der Monotherapie (n=68) erzielte IBI363 eine mediane Gesamtüberlebenszeit von 16,1 Monaten, was deutlich über den historischen Standardbehandlungen (6,4-9,3 Monate) lag, mit einer bestätigten objektiven Ansprechrate (ORR) von 13,6% bei 1 mg/kg alle zwei Wochen. In Kombination mit Bevacizumab (n=73) zeigte die Behandlung eine bestätigte ORR von 15,1% und eine Krankheitskontrollrate von 61,6% bei einer medianen progressionsfreien Überlebenszeit (PFS) von 4,7 Monaten. Besonders Patienten ohne Lebermetastasen erzielten bessere Ergebnisse mit einer ORR von 31,3% und einer PFS von 7,4 Monaten. Das Sicherheitsprofil war beherrschbar, wobei 27,9% bzw. 35,6% der Patienten in der Mono- bzw. Kombinationsbehandlung Grad-3- oder höhergradige behandlungsbedingte Nebenwirkungen (TRAEs) erlebten.
Positive
  • IBI363 monotherapy demonstrated significant survival benefit with 16.1 months median OS vs 6.4-9.3 months for standard treatments
  • Combination therapy with bevacizumab showed promising efficacy with 15.1% ORR and 61.6% DCR
  • Strong efficacy in non-liver metastasis patients with 31.3% ORR and 7.4 months PFS
  • Manageable safety profile with no new safety signals observed
Negative
  • Relatively modest ORR of 13.6% for monotherapy at 1 mg/kg Q2W dosing
  • Overall response rates remain relatively low compared to standard treatments in other cancer types
  • Grade 3 or higher adverse events affected 27.9% of monotherapy and 35.6% of combination therapy patients

SAN FRANCISCO, and SUZHOU, China, June 1, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that the clinical data of IBI363 (first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein) monotherapy and combo-therapy with bevacizumab in advanced colorectal cancer were orally presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. IBI363 demonstrated encouraging response and overall survival benefit in the context of colorectal cancer, which is typically considered an immunologically 'cold' tumor, supports its unique mechanism of actions (MoA) of turning "cold tumor" into "hot tumor".

Innovent Biologics is conducting clinical studies in China, the United States, and Australia to explore the efficacy and safety of IBI363 for multiple tumor indications, including immune resistance, cold tumors, and front-line treatments. At this year's ASCO meeting, IBI363 reported encouraging Phase 1/2 clinical data in the first three indications explored—non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and melanoma—focusing on IO-resistant and cold tumors. The data comprehensively demonstrated the breakthrough clinical outcomes of IBI363 across these indications, from robust tumor response to long-term survival benefits. These findings provide strong support of the drug's novel mechanism of action translating effectively into clinical outcomes, and imply its potential for broader clinical development, offering new hope in areas of immunotherapy where treatment options remain limited.

PD-1/IL-2α-bias bispecific antibody fusion protein IBI363 monotherapy and combined with bevacizumab in participants with advanced colorectal cancer: results from Phase 1 studies

Two Phase 1 studies (NCT05460767, NCT06717880) were conducted to evaluate the safety, tolerability and preliminary efficacy of IBI363 monotherapy and combined with bevacizumab in patients with advanced colorectal cancer.

IBI363 monotherapy has demonstrated breakthrough antitumor therapeutic potential, showing a significant extension of overall survival compared to data of standard-of-care therapies

  • As of the data cutoff date (Apr 7th, 2025), a total of 68 participants with advanced colorectal cancer received IBI363 monotherapy at the dose levels from 0.1 mg/kg to 3mg/kg. No patients were confirmed as microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR). 86.8% of patients were microsatellite stable (MSS) or proficient mismatch repair (pMMR). 61.8% of patients had liver metastases. 63.2% of patients had previously received 3 or more lines of systemic anti-tumor treatments. 23.9% of patients had received prior immunotherapy.
  • Notably, among patients receiving monotherapy with IBI363 (n=68), with a median follow-up time of 20.1 months, the median overall survival (OS) reached 16.1 months, demonstrating a significant improvement compared to the historical data of standard treatments (ranging from 6.4 to 9.3 months1-3).
  • Subgroup analyses revealed that patients with or without liver metastasis both showed excellent overall survival (OS), indicating significant clinical benefit. The median OS were 14.4 months (with liver metastasis) and 17.0 months (without liver metastasis).
  • Among patients treated with monotherapy of IBI363 1 mg/kg every 2 weeks (Q2W) (n=22), the confirmed objective response rate (cORR) was 13.6%.

Liver metastasis
(n = 42)

without liver metastasis
(n = 26)

Total

(n = 68)

Median OS, month (95% CI)

14.4 (8.0, 18.8)

17.0 (9.9, NC)

16.1 (10.1, 18.8)

6-month OS rate, % (95% CI)

81.3 (64.6, 90.6)

80.0 (58.4, 91.1)

80.7 (68.5, 88.6)

12-month OS rate, % (95% CI)

54.8 (36.9, 69.5)

59.5 (37.8, 75.8)

56.6 (43.0, 68.1)

18-month OS rate, % (95% CI)

37.6 (21.3, 53.9)

44.8 (24.0, 63.6)

40.3 (27.2, 53.0)

OS median follow-up time, month (95% CI)

20.2 (17.9, 20.7)

20.1 (16.8, 21.7)

20.1 (17.7, 20.6)

The combination of IBI363 and bevacizumab demonstrated encouraging efficacy signals and a manageable safety profile, with excellent data on objective response rate and progression-free survival

  • As of the data cutoff date (Apr 7th, 2025), a total of 73 patients with advanced colorectal cancer received IBI363 （dose levels from 0.6 mg/kg to 3mg/kg） and bevacizumab combination therapy. No patients were confirmed as MSI-H or dMMR. 91.8% of patients were MSS or pMMR. 56.2% of patients had liver metastases. 54.8% of patients had previously received 3 or more lines of systemic anti-tumor treatments. 16.4% of patients had received prior immunotherapy.
  • In all participants treated with IBI363 in combination with bevacizumab (n=73), the cORR was 15.1% and the disease control rate (DCR) was 61.6%. With a median follow-up time of 9.9 months, the median progression free survival (PFS) reached 4.7 months. With a median follow-up time of 9.4 months, OS was not mature, with events in only 13 participants (17.8%).
  • As for the combination therapy in patients without liver metastases (n=32), the confirmed ORR was 31.3%, with a DCR of 81.3%. The median PFS reached to 7.4 months.
  • In those participants who received IBI363 at 3 mg/kg Q3W plus bevacizumab (n=31), confirmed ORR and DCR increased to 19.4% and 71.0%, respectively. The median PFS increased to 5.6 months.

IBI363 3 mg/kg Q3W +Bevacizumab

(n = 31)

Without liver metastasis
(n = 32）

Total

(n = 73)

Confirmed ORR, % (95% CI)

19.4 (7.5, 37.5)

31.3 (16.1, 50.0)

15.1 (7.8, 25.4)

DCR, % (95% CI)

71.0 (52.0, 85.8)

81.3 (63.6, 92.8)

61.6 (49.5, 72.8)

Median PFS, month (95% CI)

5.6 (2.5,6.8)

7.4 (4.1, 9.8)

4.7 (2.5,6.7)

PFS median follow-up time, month (95% CI)

8.6 (7.2, 10.2)

9.9 (7.2, 13.1)

9.9 (7.2, 13.9)

  • In terms of safety, among participants receiving monotherapy and combination therapy, 19 (27.9%) and 26 (35.6%) reported treatment-related adverse events (TRAEs) of Grade 3 or higher, respectively. The most common TRAEs were arthralgia, anemia, rash, and hypothyroidism. No new safety signals were observed, with a manageable risk-benefit profile in IBI363 alone or in combination with bevacizumab.

Tumor immune cell infiltration analysis supports the IBI363 MOA of turning "cold tumor" into "hot tumor", demonstrating enrichment of PD1+CD25+CD8+ cells in baseline tumor tissue association with clinical efficacy

  • In baseline tumor tissues, elevated infiltration of CD8+ cells, CD25+CD8+ cells, and PD1+CD25+CD8+ cells were associated with improved clinical response to IBI363 monotherapy (partial response or stable disease). This supports the potential anti-tumor effects of IBI363 in the treatment of colorectal cancer from the perspective of its mechanism of action.

Professor Tao Zhang, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, stated: "Colorectal cancer is the third most common cancer type globally and ranks fourth in cancer-related mortality4. About 86% of colorectal cancer are in an immune 'desert' or immune-inflamed suppressed state, rendering traditional immune checkpoint inhibitors (ICIs) ineffective5. For colorectal cancer that has failed standard treatments, there are limited therapeutic options with short survival periods, representing a significant unmet clinical need6. IBI363, as a PD-1/IL-2α-bias bispecific fusion protein, has demonstrated robust antitumor efficacy in preclinical studies through the effective expansion of tumor-specific CD8⁺ T cells (TST cells). Its ability to block PD-1 and stimulate TST cells holds the potential to transform 'cold' tumors into 'hot' tumors. As a monotherapy, IBI363 achieves a median survival of 16.1 months in later-line treatments, which represents a significant improvement compared to the median survival of current standard therapies and also confirms its potential with a strong 'tail effect' as a PD1 plus cytokine bispecific immunotherapy. The combination of IBI363 with bevacizumab is still under continuous follow-up, having shown promising efficacy and tolerable safety, with unique efficacy characteristics particularly in the subgroup without liver metastasis. Overall, clinical data suggest that IBI363 combined with bevacizumab holds significant promise for colorectal cancer and warrants further exploration."

Dr. Hui Zhou, Senior Vice President of Innovent, stated: "On top of the preliminary data reported at 2024 ASCO and 2024 ESMO, we are presenting more updated follow-up data and combination therapy results of IBI363 at the ASCO Congress this year. From a comprehensive body of clinical evidence that includes ORR, PFS, OS, IBI363 demonstrated robust antitumor activity of both monotherapy and combination therapy in patients with advanced colorectal cancer who are non-MSI-H/dMMR. We are eyeing on long-term survival data from high dose in longer follow-up period. And the pivotal study of IBI363 targeting advanced CRC is in plan. Observing such results in the context of colorectal cancer, which is typically considered an immunologically 'cold' tumor, further highlights the broad development potential of IBI363. It offers hope for expanding into areas where immunotherapy has been less effective or even unresponsive."

About IBI363 (First-in-class PD-1/IL-2α-bias bispecific antibody fusion protein)

IBI363 is a first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein independently developed by Innovent Biologics. It functions by both blocking the PD-1/PD-L1 pathway and activating the IL-2 pathway. The IL-2 arm of IBI363 is designed to maintain its affinity for IL-2Rα while reducing binding to IL-2Rβ and IL-2Rγ, thereby minimizing toxicity. The PD-1 binding arm not only blocks PD-1 but also selectively delivers IL-2. This approach targets and activates tumor-specific T cells that express both PD-1 and IL-2α, leading to more precise and effective activation of this T cell subpopulation. IBI363 has demonstrated robust antitumor activity in various tumor-bearing pharmacological models, but also showed outstanding efficacy in PD-1 resistance and metastasis models. 

In response to urgent clinical needs, Innovent is conducting clinical studies in China, the United States and Australia to further explore the efficacy and safety of IBI363 in various tumor indications, including immune-resistant, cold tumors, and front-line treatments. The first pivotal trial of IBI363 was initiated in 2025 for unresectable locally advanced or metastatic mucosal or acral melanoma who have not received prior systemic therapy.

IBI363 has received two fast track designations (FTD) from the U.S. FDA and two breakthrough designations (BTD) from the China NMPA, for the treatment of squamous non-small cell lung cancer and melanoma, respectively.

About Innovent

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 15 products in the market. It has 3 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center.

Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Statement:

（1）Innovent does not recommend the use of any unapproved drug (s)/indication (s).

（2）Ramucirumab (Cyramza®) and Selpercatinib (Retsevmo®) and Pirtobrutinib (Jaypirca®) were developed by Eli Lilly and Company.

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions.

Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.

References

1. Dasari A, et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet. 2023 Jul 1;402(10395):41-53.

2. Grothey A, et al. CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013 Jan 26;381(9863):303-12.

3. Mayer RJ, et al. Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer. N Engl J Med. 2015 May 14;372(20):1909-1919. doi: 10.1056/NEJMoa1414325.

4. https://publications.iarc.fr/Databases/Iarc-Cancerbases/GLOBOCAN-2012-Estimated-Cancer-Incidence-Mortality-And-Prevalence-Worldwide-In-2012-V1.0-2012.

5. Huyghe N, et al. Biomarkers of Response and Resistance to Immunotherapy in Microsatellite Stable Colorectal Cancer: Toward a New Personalized Medicine. Cancers (Basel). 2022 Apr 29;14(9):2241.

6. O'Neil BH, et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma. PLoS One. 2017 Dec 28;12(12):e0189848.

 

Cision View original content:https://www.prnewswire.com/news-releases/2025-asco-oral-presentation-innovent-biologics-announces-updated-date-of-ibi363-first-in-class-pd-1il-2-bias-bispecific-antibody-fusion-protein-from-phase-1-clinical-studies-in-advanced-colorectal-cancer-302470217.html

SOURCE Innovent Biologics

FAQ

What are the key results of IBI363 in the ASCO 2025 colorectal cancer trial?

IBI363 showed 16.1 months median overall survival as monotherapy, and in combination with bevacizumab achieved 15.1% ORR and 61.6% DCR with 4.7 months median PFS

How does IBI363's survival benefit compare to standard treatments for colorectal cancer?

IBI363 demonstrated 16.1 months median overall survival, significantly better than historical standard treatments ranging from 6.4 to 9.3 months

What is the safety profile of IVBIY's IBI363 in colorectal cancer treatment?

The safety profile was manageable with 27.9% of monotherapy and 35.6% of combination therapy patients experiencing Grade 3+ adverse events, mainly including arthralgia, anemia, rash, and hypothyroidism

How effective is IBI363 in patients without liver metastasis?

Patients without liver metastasis showed better outcomes with 31.3% confirmed ORR, 81.3% DCR, and 7.4 months median PFS

What is unique about IBI363's mechanism of action in colorectal cancer?

IBI363 is a first-in-class PD-1/IL-2α-bias bispecific antibody that can turn 'cold' tumors into 'hot' tumors by expanding tumor-specific CD8+ T cells
Stock IVBIY logo
Innovent Biologi

OTC:IVBIY

IVBIY Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

IVBIY Latest News

Jun 2, 2025
2025 ASCO Presentation: Innovent Biologics Announces Updated Data of IBI354 (Novel anti-HER2 ADC) From the Phase 1/2 Clinical Study in Advanced Ovarian Cancer, Breast Cancer and Other Solid Tumors
Jun 2, 2025
ASCO 2025 Oral Presentation: Innovent Biologics Announces Updated Data of IBI343 (Novel Anti-CLDN18.2 ADC) From the Phase 1 Clinical Study in Patients with Advanced Pancreatic Cancer
May 31, 2025
ASCO 2025 Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-in-class PD-1/IL-2α -bias Bispecific Antibody Fusion Protein) from Phase 1 and 2 Clinical Studies on Immunotherapy-treated Advanced Malignant Melanoma
May 28, 2025
Innovent Announces a Phase 3 Study of Picankibart (Anti-IL-23p19 Antibody) Completes First Participant Dosing, Exploring Biologics Switching Treatment for Psoriasis Patients with Prior Inadequate Response to Anti-IL-17 Antibodies
May 25, 2025
Phase 3 Clinical Study of Mazdutide in Chinese Adults with Overweight or Obesity (GLORY-1) Published in The New England Journal of Medicine (NEJM)

IVBIY Stock Data

7.97B
91.64M
Biotechnology
Healthcare
Link
China
Suzhou

Related Articles

Continue reading with these related stories

View All Latest News